Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

April Reynolds

Nurse Practitioner, Family Great Falls, MT Nurse Practitioner

NPI 1609219211 CMS profile 10473605

500 15Th Ave S, Great Falls, MT 59405

Open in the dashboard

General payments

$2,414

152 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, April Reynolds of Great Falls, MT is reported in the CMS Open Payments database as having received $2,414 across 152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20 1
2023 General $507 28
2022 General $878 67
2021 General $1,011 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • April Reynolds
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to April Reynolds were reported at $20. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year April Reynolds Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,011 $124 $35–$379 $132
2022 $878 $141 $44–$430 $149
2023 $507 $154 $49–$476 $160
2024 $0 $165 $51–$504 $164
2025 $20 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $656 35 payments
  2. AbbVie, Inc. $354 36 payments
  3. Esperion Therapeutics, Inc. $191 14 payments
  4. Amgen Inc. $157 10 payments
  5. AstraZeneca Pharmaceuticals LP $117 5 payments
  6. Abbott Laboratories $101 5 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $100 6 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $91 5 payments
  9. Amarin Pharma Inc. $76 4 payments
  10. Sanofi-Aventis U.S. LLC $69 4 payments
  11. Other $502 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,403 151 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $449 24 payments
  2. RYBELSUS $327 23 payments
  3. NEXLETOL $191 14 payments
  4. UBRELVY $137 15 payments
  5. VRAYLAR $134 12 payments
  6. Repatha $120 8 payments
  7. Otezla $120 8 payments
  8. FARXIGA $104 4 payments
  9. Kerendia $100 6 payments
  10. NURTEC ODT $91 5 payments
  11. Other $1,295 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$39,053

Medicare's payments for the services billed

Medicare patients

253

Average age 77

Services billed

518

128 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Depression 48%
Diabetes 44%
Ischemic heart disease 39%
Chronic kidney disease 35%
Atrial fibrillation 34%
COPD 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record